Archive · 6 Aug 2025
Aurobindo Pharma Q1 Profit Down 10%, Elara Capital Maintains Buy
Aurobindo Pharma, a drug company, saw its profits go down a bit.
However, experts at Elara Capital still think the company is a good investment.
The company is working on new versions of medicines called biosimilars.
A factory producing a key ingredient, Penicillin-G, had a setback, but is expected to increase production soon.
The company's business in Europe is growing, but sales in the US are a concern.
Aurobindo Pharma's Q1 FY26 profit declined 10% year-over-year.
Elara Capital maintains a 'Buy' call on the company.
The company has 14 biosimilars in its pipeline and has filed 3 for EU approval.
Penicillin-G production was affected by a fire and is expected to ramp up by September.
EU business grew by 9% YoY; US sales decreased by 4% YoY.
- Who
- Aurobindo Pharma
- What
- Aurobindo Pharma's Q1 FY26 profit declined by 10%.
- When
- Q1 FY26
- Where
- EU and US markets
- Why
- Due to a fire incident in the Penicillin-G production facility and US sales decrease.
EU vs US Markets
Future Projections
Market Performance
EU vs US Markets
Growing EU business
Future Projections
Declining US sales
- Profit Decline
- 10% YoY
- EU Business Growth
- 9% YoY
- US Sales Decline
- 4% YoY
- Biosimilars in Pipeline
- 14
- Biosimilars Filed for EU
- 3
